“HBRN and Current Status of HBV therapy”
February 11, 2015
12:00 PM (EDT) - 1:00 PM (EDT)
BRB II/III Auditorium
Marc Ghany, MD, MHSc
Staff Physician, Liver Diseases Branch
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Bethesda, Maryland
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, medical students, nurses, nurse practitioners, physician assistants and allied health professionals in the medical specialties of infectious disease, hepatology, gastroenterology, and internal medicine
Educational Objectives
After completing this activity, participants should be able to:
- Demonstrate increased understanding of the epidemiology of and risk factors for viral hepatitis.
- Increase the rate of testing for viruses associated with hepatitis.
- Demonstrate improved knowledge, competence and clinical practice in terms of the current standards and guidelines for the management of patients with viral hepatitis.
- Demonstrate an improved understanding of the treatment of viral hepatitis in patient co-infected with HIV or other viral infections.
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgement of Commercial Support*
Gilead Sciences Medical Affairs, BoehringerIngelheim Pharmaceuticals, Inc., Jansen Therapeutics, Division ofJanssen Products, LP, AbbVie Inc., Vertex Pharmaceuticals, Inc.
For more information, please contact
Richard Gordon
847-951-5318
xx
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, Director of CMEandthe peer reviewerZalman Agus, MD, Associate Dean for CME, have disclosed that they have norelevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:
Planning Committee Member Name
Brian Boyle / Oliver Fultz / Rick GordonMila Kostic / Michael Schoen, PhD
Presenter Name
Marc Ghany, MD, MHSc
The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity.
Planning Committee Member NameName of Commercial InterestRelationship
David Kaplan, MDBayer PharmaceuticalsResearch Support
Ian Frank, MDGilead, ViiVHonorarium
JanssenConsultant
GlaxoSmith Kline, Bavarian NordicResearch Support
K. Rajender Reddy, MDJanssen, Merck, Genentech-Roche, Gilead, BMS, AbbvieHonorarium
Janssen, Merck, Gilead, BMS, AbbvieResearch Support
Mark Sulkowski, MDAbbVie, BMS, Gilead, Merck, Janssen, BIPIResearch Support
Abbvie, BMS, Gilead, Merck, Janssen, TobiraScientific Advisor
GileadDSMB
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected
Presenter nameProduct
MARC GHANY, MD, MHSCGS-7340 (prodrug-tenofovir); ARC 520 (RNAi), Isis HBV-Rx antisense, MycB entry inhibitor,
NVR1221 capsid inhibitor, GS-4774 (vaccine), GS9620 Toll-7, DV601 Vac+nuc acid adjuvant, RepA9 sAg inhibitor, BAY41-109 capsid